Investors
EastGate Biotech Pakistan Expands its Collaboration in Advancing the Development of a New Vaccine Against COVID-19
February 18, 2020
Joint Venture Collaboration to also pursue antibiotic products to create a pipeline to fight various new strains of flu illnesses
Read moreEastGate Biotech Discusses Their Phase 3 Clinical Trials and Recent Coronavirus Agreement
February 5, 2020
EastGate Biotech Discusses Their Phase 3 Clinical Trials and Recent Coronavirus Agreement
Read moreEastGate Biotech Pakistan Receives International Marketing Rights of Anaferon an Approved Coronavirus Treatment to Potentially Combat the Wuhan Coronavirus
January 30, 2020
EastGate Biotech Corp. announced today that the company along with its partner EastGate Biotech Pakistan has signed a Memorandum of Understanding (MOU) for the international marketing rights of Anaferon for the treatment of the novel 2019 Coronavirus, commonly called the Wuhan Coronavirus
Read moreEastGate Biotech Provides Summary of 2019 Corporate and Development Highlights
December 30, 2019
Eastgate Biotech Corp. provides a end of year 2019 Corporate and Development Highlights.
Read moreEastGate Biotech Expands Pipeline to Alzheimer’s Disease Using its Alternative Insulin Delivery Platform
November 14, 2019
EastGate Biotech Corp. announced today that it has initiated plans to expand its alternative insulin delivery portfolio to apply to the treatment of Alzheimer’s disease.
Read moreEastGate Biotech Announces Expansion and Restructuring of Joint Venture with its Partner in Pakistan
October 9, 2019
Key products to be tested, registered and marketed include Insugin for diabetes application, alternative insulin for Alzheimer’s application, and Blood Plasma Derived Products, Human Serum Albumin 20%
Read moreEastGate Biotech Receives Regulatory Approval to Initiate a Phase III 90-day clinical trial on Insugin, its liquid insulin mouth rinse solution.
September 25, 2019
The Marketing Application Approval in Pakistan will follow subject to completion of the Phase III clinical study that will include up to 200 Type 2 patients.
Read moreEastgate Biotech Corp (OTC: ETBI) Management Interview
September 11, 2019
Eastgate’s new COO took time to discuss his role with the company, ETBI’s licensing strategy, and upcoming goals for the next few months which includes the commencement of the Phase III trial for their flagship product, Insugin.
Read moreEastGate Biotech Announces Appointment of Bill Abajian to Lead Licensing and Marketing Phase as Chief Operating Officer
September 5, 2019
WEST CALDWELL, NJ and TORONTO, ON /NEWMEDIAWIRE/ September 4, 2019/ EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical company, that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced today the appointment of distinguished executive Bill Abajian to lead the licensing and marketing phase of the company as Chief Operating Officer of the company, effective August 27, 2019.
Read moreEastGate Biotech Files Application to Initiate Phase III clinical trial for Insugin
June 26, 2019
Approximately 200 patients will be included in the Phase III study in order to achieve regulatory approval in Pakistan
Read more